A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma

Journal of Nuclear Medicine

Volumn 49, Issue 12, 2008, Pages 1912-1921

  Park, Joong Won ^a   Ji, Hoon Kim ^a   Seok, Ki Kim ^a   Keon, Wook Kang ^a   Kyung, Woo Park ^a   Choi, Jun Il ^a   Woo, Jin Lee ^a   Kim, Chang Min ^a   Byung, Ho Nam ^a  

^a National Cancer Center   (South Korea)

Author keywords

Acetate; FDG; Hepatocellular carcinoma; Hepatology; Oncology; PET CT; Sensitivity

Indexed keywords

ACETIC ACID C 11; ALPHA FETOPROTEIN; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; HEPATITIS B SURFACE ANTIGEN; SUPERPARAMAGNETIC IRON OXIDE; ACETIC ACID DERIVATIVE; CARBON; CARBON 11 ACETATE; CARBON-11 ACETATE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CELL DIFFERENTIATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG EXCRETION; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CANCER; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TUMOR BIOPSY; TUMOR DIFFERENTIATION; EVALUATION; IMAGE SUBTRACTION; INCIDENCE; KOREA; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICS; SURVIVAL; SURVIVAL RATE;

ACETATES; ADULT; CARBON; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INCIDENCE; KOREA; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; SURVIVAL ANALYSIS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 57149101558     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.055087     Document Type: Article

References (30)

1. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
2. Jonas S, Bechstein WO, Steinmüller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080-1086.
3. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430.
4. Park JW, An M, Choi JI, et al. Accuracy of clinical criteria for the diagnosis of hepatocellular carcinoma without biopsy in a hepatitis B virus-endemic area. J Cancer Res Clin Oncol. 2007;133:937-943.
5. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369-1379.
6. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003;44:213-221.
7. Chen YK, Hsieh DS, Liao CS, et al. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res. 2005;25:4719-4725.
8. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol. 2004;39:961-968.
9. Bohm B, Voth M, Geoghegan J, et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol. 2004;130:266-272.
10. 11C-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181-186.
11. Ho CL, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med. 2007;48:902-909.
12. 18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg. 2003;69:117-124.
13. Park JW, for the Korean Liver Cancer Study Group and National Cancer Center. Practice guideline for diagnosis and treatment of hepatocellular carcinoma [in Korean]. Korean J Hepatol. 2004;10:88-98.
14. Party IW. Terminology of nodular hepatocellular lesions. Hepatology. 1995;22:983-993.
15. 11C carbon dioxide production target. Appl Radiat Isot. 2002;57:857-860.
16. Kim S, Chung JK, Kim BT, et al. Relationship between gastrointestinal F-18-fluorodeoxyglucose accumulation and gastrointestinal symptoms in wholebody PET. Clin Positron Imaging. 1999;2:273-279.
17. Nagaoka S, Itano S, Ishibashi M, et al. Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings. Liver Int. 2006;26:781-788.
18. Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007;13:427-433.
19. Shiomi S, Nishiguchi S, Ishizu H, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol. 2001;96:1877-1880.
20. 18F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl. 2006;12:1655-1660.
21. Sun L, Wu H, Guan YS. Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol. 2007;13:2775-2783.
22. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94:3314-3319.
23. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32:792-797.
24. Iwata Y, Shiomi S, Sasaki N, et al. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med. 2000;14:121-126.
25. Verhoef C, Valkema R, de Man RA, Krenning EP, Yzermans JN. Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography. Liver. 2002;22:51-56.
26. 18F-FDG positron emission tomography for evaluation of hepatocellular carcinoma [in Korean]. Korean J Hepatol. 2006;12:546-552.
27. Park KW, Park JW, Choi JI, et al. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol. 2008;23:467-473.
28. Hatano E, Ikai I, Higashi T, et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg. 2006;30:1736-1741.
29. Fujimoto R, Higashi T, Nakamoto Y, et al. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET. Ann Nucl Med. 2006;20:399-408.
30. Watanabe J, Nakashima O, Kojiro M. Clinicopathologic study on lymph node metastasis of hepatocellular carcinoma: a retrospective study of 660 consecutive autopsy cases. Jpn J Clin Oncol. 1994;24:37-41.